High-dose methotrexate and interferons for pleural mesothelioma
Author Information
Author(s): Halme M, Knuuttila A, Vehmas T, Tammilehto L, Mäntylä M, Salo J, Mattson K
Primary Institution: Helsinki University Central Hospital
Hypothesis
Can high-dose methotrexate combined with interferons effectively treat malignant pleural mesothelioma?
Conclusion
The combination of high-dose methotrexate and interferons is active against malignant pleural mesothelioma and is well-tolerated.
Supporting Evidence
- Seven partial responses were observed among 24 patients evaluable for response.
- Median duration of response was 10 months.
- Median survival was 17 months.
- 1-year survival rate was 62%.
- 2-year survival rate was 31%.
- The toxicity of the chemo-immunotherapy was acceptable.
- Treatment was stopped in one patient due to grade IV neurological toxicity.
- MTX dose reductions were rare.
Takeaway
Doctors gave a special medicine to 26 patients with a type of lung cancer, and many of them felt better for a while.
Methodology
Patients were treated with high-dose methotrexate and interferons, with responses evaluated after treatment.
Potential Biases
Potential selection bias due to the small number of patients.
Limitations
The study had a small sample size and limited follow-up.
Participant Demographics
Patients had pleural mesothelioma of UICC stage I–IV, with varying stages represented.
Statistical Information
Confidence Interval
95% CI 13–51%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website